Loading clinical trials...
Loading clinical trials...
Multi-Center, Prospective, Consecutive, Paired Diagnosis, Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic stroke). Stroke is a medical emergency and must be quickly diagnosed and treated. Computed tomography (CT) or magnetic resonance imaging (MRI) scans are commonly used to diagnose stroke, but they are not always readily available. EMVision has developed the emu™ Brain Scanner, a helmet-like device which scans the head using ultra-high frequency radio signals. It is portable and easy to use, making it more accessible than CT or MRI machines. Easier access to the EMVision emu™ Brain Scanner may reduce the time taken to diagnose stroke, leading to faster treatment and better health outcomes. It is the purpose of this study in the first instance to determine the accuracy of the EMVision emu™ Brain Scanner in the detection of haemorrhagic stroke.
This clinical investigation is a paired diagnosis, diagnostic performance study intended to quantify the accuracy of the emu™ Brain Scanner's diagnostic output in comparison to current gold-standard practices including multi-modal neuroimaging by CT and/or MRI. Any adult with neurological deficit suspected to be stroke presenting to the investigational site's emergency department shall be considered as potentially eligible for the study. Potential participant's eligibility for the study is determined via screening evaluation which includes a review of available demographic and medical history information against the study's inclusion and exclusion criteria, as well as a head size assessment using provided gauges to confirm that their head would fit within the emu™ Brain Scanner. If the screening evaluation finds that the participant is eligible for the study then the investigator proceeds with the informed consent process. This activity occurs in parallel with the investigational site's standard practices for stroke patient management, ensuring no delay in these patients' care. Regardless of study participation, participants will receive the complete standard of care diagnostic workflow in accordance with applicable national and international guidelines, as well as practices established at the investigational site. The standard of care diagnostic workflow is centered around acute baseline multi-modal CT imaging (and in some instances MRI). Directly following or before this imaging, and without delaying subsequent treatment, a scan is completed with the emu™ Brain Scanner to allow timely coordination between the investigational emu™ Brain Scan result and the reference standard CT/MRI imaging. If the attending physician perceives any potential risk of delaying treatment of the patient then that patient is strictly exclude from the study, entirely at the attending physician's discretion. A central adjudicating ground truth diagnosis panel is formed of experts in the area of stroke diagnosis and reviews all diagnostic information gathered by the investigational site as per the site's standard of care diagnostic workflow. The ground truth diagnosis panel is blinded to the output from the emu™ Brain Scanner and defines the 'ground truth' or 'reference standard' diagnosis for each patient to ensure accuracy and consistency. Integral to the ground truth diagnosis panel's consideration is the assessment by the core imaging lab, who similarly review all imaging provided by the investigational sites to ensure consistent input to the ground truth expert panel. The result of the emu™ Brain Scan is compared to the ground truth diagnosis by a biostatistician to determine the accuracy of the emu™ Brain Scanner's diagnostic output (in terms of sensitivity and specificity) with the first output evaluated being intracranial haemorrhage detection in suspected stroke patients. The biostatistician then performs all statistical analyses against the study objectives in accordance with the Statistical Analysis Plan.
Age
22 - No limit years
Sex
ALL
Healthy Volunteers
No
Mayo Jacksonville
Jacksonville, Florida, United States
UTHealth
Houston, Texas, United States
Liverpool Hospital
Liverpool, New South Wales, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Start Date
March 26, 2025
Primary Completion Date
November 1, 2026
Completion Date
November 28, 2026
Last Updated
June 13, 2025
300
ESTIMATED participants
Brain Scan
DIAGNOSTIC_TEST
Lead Sponsor
EMVision Medical Devices Ltd
NCT05093673
NCT07371455
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06258538